Warsaw's primary care market faces outdated GP practices, a wave of retirements, endless red tape and limited access to quality care. Jutro Medical offers an AI-first rollup model that enables physicians to focus on their patients by acquiring clinics and integrating them into a unified platform of smart agents that handle EHR, workflow, and administrative tasks.
The organization has just raised a €24 million Series A extension led by Warsaw Equity Group with participation from Vinci, naturalX Health Ventures, Fluent Ventures, Aternus, KAYA VC, and Inovo VC, with additional financing from mBank and Orbit Capital, bringing the total Series A total to €36 million.
Introducing AI-first primary care in Europe
After observing first-hand the chaos in Polish clinics, Adam Janczewski founded Jutro Medical in 2020, bringing his technology expertise to the mission of blending online and offline care and leveraging AI to reduce bureaucracy. Born out of frustration with the limitations of telemedicine and the retirement of general practitioners, Janczewski's team built a four-year software foundation to scale.
The ultimate goal is to redefine publicly funded primary care, with AI agents managing thousands of interactions each month and allowing doctors to leave their desks and perform actual medical care. Jutro's EHR provides AI agents with virtual consultations, prescriptions, tests, and medical certificates, and hands off complex cases to the same doctor at one of the company's owned clinics for seamless continuity.
Other features include clinic integration, 4.94/5 visit ratings from over 500,000 practices, and 86 NPS with AI-assisted 1,500 doctor visits in the last month alone. Unlike Babylon Health, Kry, and eMedica, Jutro's integrated operations drive benefits and quality for our 120,000 patients, and we outperform them by owning the entire stack.
What's next?
This year, fresh cash has fueled more than 20 clinic purchases per year in Poland, followed by a pan-European rollout targeting €1 billion in revenue while keeping EBITDA close to breakeven with 270% year-on-year growth.
